Hemostats Market (2025-2032)
The Hemostats Market was valued at $3.11 billion in 2024. This market is expected to reach $5.32 billion by 2032, from an estimated $3.34 billion in 2025, at a CAGR of 6.9% during the forecast period 2025-2032. Hemostats Market Size & Forecast The growth of this market is driven by the increasing
- Published
- Jan 2024
- Pages
- 280
- Format
- PDF + Excel
- Report ID
- MRHC - 1041150
- Base year
- 2024
- 2024 · BASELINE
- $3.11B
- 2032
- $5.32B
- CAGR 2025–2032
- 6.9%
2024 baseline · 2025–2032 forecast at 6.9% CAGR · hover a bar for the value
Key highlights
By Type: In 2025, the Absorbable Hemostats Segment to Dominate the Hemostats Market
By Application: In 2025, the Surgery Market Segment to Dominate the Hemostats Market
By Form: In 2025, the Matrix and Gel Segment Dominate the Hemostats Market
By End User: In 2025, the Hospitals & Clinics Segment to Dominate the Hemostats Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~ 280 |
| Format | |
| Forecast Period | 2025–2032 |
| Base Year | 2024 |
| CAGR (Value) | 6.9% |
| Market Size (Value) | USD 5.32 Billion by 2032 |
| Segments Covered | By Type · Absorbable Hemostats · Mechanical or Passive Agents · Gelatin-based Hemostat · Collagen Hemostat · Oxidized Regenerated Cellulose Hemostat · Flowable and Active Agents · Thrombin-based Hemostat · Combination Hemostat · Other Absorbable Hemostat · Non-absorbable Hemostats · Fibrin Sealants · Synthetic Sealants · Hemostatic Gauze · Hemostatic Forceps · By Application · Surgery · Orthopedic Surgery · General Surgery · Gynecology Surgery · Cardiovascular Surgery · Neurosurgery · Plastic Surgery · Other Surgeries · Dental Treatments · Traumatic Injury · By Form · Sponges and Dressings · Sheets and Pads · Powder · Matrix and Gel · Tools · By End User · Hospitals & Clinics · Ambulatory Surgical Centers · Nursing Homes |
| Countries Covered | North America (U.S., Canada), Europe (France, Germany, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa |
| Key Companies | Baxter International Inc. (U.S.), Pfizer Inc. (U.S.), B. Braun Melsungen AG (Germany), C. R. Bard, Inc. (U.S.), Integra LifeSciences (U.S.), Medtronic plc (Ireland), CSL Behring (U.K.), Gelita Medical GmbH (Germany), Grifols, S.A. (Spain), Abbott Laboratories (U.S.), CryoLife (U.S.), Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson.), Medtronic plc (Ireland), Becton, Dickinson and Company (BD) (U.S.), and Advanced Medical Solutions Group plc (U.K.). |
Report overview
Segments covered: type, absorbable hemostat, mechanical or passive agent, gelatin-based hemostat, collagen hemostat, oxidized regenerated cellulose hemostat, flowable, active agent, thrombin-based hemostat, combination hemostat, other absorbable hemostat, non-absorbable hemostat, fibrin sealant, synthetic sealant, hemostatic gauze, hemostatic forcep, application, surgery, orthopedic surgery, general surgery, gynecology surgery, cardiovascular surgery, neurosurgery, plastic surgery, other surgery, dental treatment, traumatic injury, form, sponge, dressing, sheet, pad, powder, matrix, gel, tool, end user, hospitals & clinic, ambulatory surgical center, nursing home. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular, orthopedic, and neurological diseases and subsequent increase in the volume of surgical procedures; increasing rate of accidents; rise in the number of cesarean deliveries, fatal injuries, and organ transplantation; increased R&D activities; rising healthcare spending; and growing preference for minimally invasive surgical procedures. Additionally, the increasing use of advanced hemostats, advancements in dental hemostatic agents, and increasing demand for preloaded applicators and ready-to-use hemostats are expected to offer significant market growth opportunities.
However, allergic reactions caused by the material used in making hemostats restrain the growth of this market. Additionally, the high manufacturing price for hemostats poses a significant challenge to the market's growth. Furthermore, biopolymer-based hemostats and dual-action hemostatic technology are trends prevailing in the hemostats market.
Report infographic
Market dynamics
6 factors across 2 forcesIncreasing Rate of Road Accidents
The rate of accidents has increased over the years. As per the U.S. Department of Health & Human Services, January 2024 report, road traffic crashes are among the leading causes of death in the U.S. Similarly, approximately 20,653 people were killed in road accidents in the EU, an increase of 3.7% compared to 2021 (Source: European Commission, Directorate-General for Communication). The increasing number of accidents has increased the number of hospital visits by patients for minor and major surgeries and wound care, driving the demand for hemostatic products in hospitals & clinics.
Growing Adoption of Minimally Invasive Surgical Procedures
The rate of minimally invasive surgeries (MIS) has been increasing in recent years. These surgeries necessitate tiny incisions, which creates demand for advanced hemostatic agents or tamponing agents to control blood loss.
With developments in minimally invasive surgery (MIS) approaches and technologies, MIS is becoming more popular in a variety of surgical disciplines, particularly cardiac surgery for coronary artery bypass surgery (CABG), valve surgery, and orthopedic surgery for hip and knee replacements. Furthermore, the adoption of minimally invasive surgeries is growing due to the benefits offered over traditional surgeries, such as easy and faster blood flow control, leading to shorter healing time and hospital stay, fewer complications, and less pain. Hemostats act as a powerful tool for surgeons to achieve hemostasis in these complicated surgeries. According to the American Society of Plastic Surgeons, in 2022, 682,932 non-invasive fat reduction surgeries and 408,970 non-invasive skin tightening surgeries were conducted in the U.S. Minimally invasive techniques frequently require operating complex cases as doctors limit the size and number of cuts or incisions. Hemostats created expressly for these procedures provide precision bleeding control, enabling surgeons to accomplish correct hemostasis.
Hemostats Market Trends
The Growing Popularity of Biopolymer-based Hemostats
Biopolymer-based hemostats are becoming popular in surgical hemostasis. These materials may assist with bleeding and come in a variety of forms, including particles, powder, sponges, sheets, foams, films, and hydrogels. Biopolymers have proven their applications as hemostatic materials due to their capabilities as biodegradable, biocompatible, and bioactive.
Biopolymer-based hemostats are meant to be biocompatible, which means the body easily absorbs them and does not trigger adverse reactions. The materials implemented in hemostats are selected with care to reduce the chance of immunological reactions and inflammation. Biopolymer-based hemostats provide a possible alternative to conventional hemostatic approaches. Their biocompatibility, absorbability, and hemostatic effectiveness make them particularly suitable choices for surgical treatments. As biopolymer technology research and development progresses, it is expected to bring more advances and higher adoption of biopolymer-based hemostats in clinical practice.
Dual-action hemostatic technology
Dual-action hemostatic technology effectively and promptly controls gingival bleeding. This technology approach ensures a comprehensive solution for managing bleeding during dental treatments. Dual-action hemostatic technology characteristics include effectivity and reliability, pose no biological risk in-vivo, are free from side effects, and stop bleeding quickly. Dual-action hemostatic technology achieves hemostasis in deep and complex wounds with secluded hemorrhagic sites. Additionally, the sealing capabilities provide suture support in vascular surgery, which is highly demanded by surgeons. Additionally, the rising preference for these hemostats is due to their dual mechanism of action, which involves the interaction of two different components which include collagen mediation of intrinsic hemostatic action liable to form fibrin clots and speedy adherence to applied tissue due to the electrophilic cross-linking with a protein-reactive polyethylene glycol monomer. Such advantages of dual-action hemostatic technology are expected to drive the hemostats market.
Table of contents
12 chapters · 126 sections · 280 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Type | Absorbable Hemostats | Non-absorbable hemostats |
| By Application | Surgery Market | — |
| By Form | Matrix and Gel | — |
| By End User | Hospitals & Clinics | — |
By Type
- The absorbable hemostats segment is expected to account for the largest share of 58.6% of the hemostats market.
- The segment’s large share is attributed to the advantages offered by absorbable hemostats, such as controlling bleeding from fistula-puncture sites, achieving hemostasis during vascular surgery, controlling capillary bleeding, availability of versatile forms of hemostats, and rapid embolization.
- However, the non-absorbable hemostats segment is projected to witness the highest growth rate of 7.6% during the forecast period of 2022–2032.
- This growth is driven by the growing use of fibrin sealants as hemostats by surgeons during surgery to physically provide an effective barrier for controlling blood flow.
- These sealants offer high biocompatibility, less time needed for clot formation, and the use of non-absorbable hemostats in high blood flow cases.
By Application
- The Surgery Market Segment to Dominate the Hemostats Market
- The surgery segment is expected to account for the largest share of the hemostats market.
- The segment’s large share is attributed to the recurrent use of various hemostatic agents in the increasing number of orthopedic, general, gynecological, and cardiovascular surgeries, the rising number of accidents and traumatic injuries leading to surgical treatments, and the use of advanced hemostats and advance sealants by healthcare professionals in minimally invasive surgeries for controlling the blood flow.
By Form
- The Matrix and Gel Segment Dominate the Hemostats Market
- The matrix and gel segment is expected to account for the largest share of 41.3% of the hemostats market.
- The segment’s large share is attributed to advantages offered by matrix and gel hemostatic agents, such as the formation of a physical matrix, promoting activation of the clotting pathway; their wide applications in patients with intact coagulation cascade; availability of bioactive and biocompatible gels; and cost efficiency.
- This segment is also projected to witness the highest growth rate of 7.2% during the forecast period of 2022–2032.
By End User
- The hospitals & clinics segment is expected to account for the largest share of the hemostats market.
- The significant market share of this segment is attributed to the rising number of patient visits for surgical procedures and traumatic injury treatment in hospitals, the increasing number of surgeries, the willingness to spend on advance hemostats by hospitals, and favorable reimbursement policies.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 32.9% of the hemostats market, followed by Europe and Asia-Pacific. In North America, the U.S. accounted for the largest share in 2025. The significant market share of the U.S. can be attributed to several key factors including the presence of key market players in the U.S., a well-established and technologically advanced healthcare infrastructure, and favorable government policies in the country.
Asia-Pacific
Fastest growthMoreover, the market in Asia-Pacific is slated to register the highest growth rate (CAGR 7.8%) due to significantly growing markets such as India and China. The growth of this market is attributed to an increase in the number of acute injuries and accidents, an increase in surgical procedures in the countries, rising medical tourism, rising healthcare expenditures, and the focus of major players in these countries due to increasing market potential.
Competitive landscape
- July 2024
Baxter International Inc. (U.S.) launched PERCLOT Absorbable Hemostatic Powder in the U.S. The powder is a ready-to-use product that can be used for intact coagulation in mild bleeding cases.
- November 2024
Ethicon, Inc. (U.S.) (Subsidiary of Johnson & Johnson) received approval for ETHIZIA, an adjunctive hemostat solution that is proven to achieve sustained hemostasis to control excess bleeding situations.
- July 2021
Medcura, Inc. (U.S.), in partnership with ASO, LLC (U.S.), a manufacturer of first aid products, launched an antibacterial hemostatic gel named Rapid-Seal. The gel provides antibacterial and rapid bleeding management capabilities that aid in wound treatment.
- July 2021
Baxter International Inc. (U.S.), through its subsidiary Baxter Healthcare Corporation, acquired PerClot Polysaccharide Hemostatic System from CryoLife, Inc. (U.S.). The acquisition will strengthen Baxter’s product portfolio in hospitals, including operating rooms.
- October 2020
Teleflex Incorporated (U.S.) will acquire privately held Z-Medica, LLC (U.S.). Z-Medica’s hemostatic technologies aid in hemorrhage control, and end users worldwide are adopting efficient bleeding control solutions.
- Baxter International Inc. (U.S.)
- Pfizer Inc. (U.S.)
- B. Braun Melsungen AG · Germany
- C. R. Bard
- Inc.(U.S.)
- Integra LifeSciences (U.S.)
- Medtronic plc · Ireland
- CSL Behring (U.K.)
- Gelita Medical GmbH · Germany
- Grifols, S.A. · Spain
- Abbott Laboratories (U.S.)
- CryoLife (U.S.)
- Becton
- Dickinson and Company (BD) (U.S.)
Frequently asked questions
This study offers a detailed assessment of the hemostats market, including the market sizes & forecasts for market segments such as type, application, form, and end user. It also provides an in-depth analysis of various segments & subsegments of the hemostats market at the regional and country levels.
Cite this report
Meticulous Research. (2024). Hemostats Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041150). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/hemostats-market-5833